CAMBRIDGE, Mass., Oct. 8, 2019 /PRNewswire/ — Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics. Founded in 2017 in Flagship Labs, Flagship’s innovation foundry, Cygnal is the first company to develop drugs in the field of exoneural biology, a new understanding of how nerves and neural signaling drive human health and disease. The company has discovered biologically relevant pathways and advanced starting points for drug targets based on exoneural biology, and its initial areas of focus are cancer and inflammatory disease. Cygnal is led by CEO Pearl Huang, Ph.D., and is based in Cambridge, Mass.
“For decades, scientists have known that the human body is interconnected by peripheral nerves that communicate with the central nervous system. Yet the traditional neurobiological view relegated these nerves to an auxiliary status,” said Noubar Afeyan, Ph.D., founder and CEO of Flagship Pioneering and co-founder of Cygnal Therapeutics. “Flagship conducted explorations into the role of nerves in health and disease, finding far-reaching and powerful connections. We created Cygnal to develop drugs based on these insights, and we believe the company will bring relief to patients in need with unprecedented exoneural medicines.”
Click here to read more.